Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
INVA
INVA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INVA News
Innoviva CEO Outlines Three-Part Growth Plan and $125M Buyback
Feb 28 2026
Yahoo Finance
Innoviva Reports Strong Q4 Earnings Results
Feb 26 2026
seekingalpha
INVA Stock Fluctuates: 52-Week Low at $16.52
Jan 06 2026
NASDAQ.COM
FDA Greenlights Innoviva's NUZOLVENCE, the First Oral Treatment for Gonorrhea
Dec 13 2025
NASDAQ.COM
Innoviva Receives FDA Approval for NUZOLVENCE to Treat Gonorrhea
Dec 12 2025
Newsfilter
Innoviva Reports Positive Phase 3 Results for Zoliflodacin in Treating Gonorrhea
Dec 12 2025
Businesswire
Innoviva Publishes Positive Phase 3 Results for Zoliflodacin in Gonorrhea Treatment
Dec 12 2025
Newsfilter
Biotech Stocks Await FDA Verdict in December 2025
Nov 27 2025
NASDAQ.COM
Cantor Fitzgerald Keeps Overweight Rating on Innoviva, Increases Price Target to $31
Nov 06 2025
Benzinga
Innoviva, Inc. Announces Rise in Q3 Earnings
Nov 06 2025
NASDAQ.COM
In-Depth Insights: 5 Analysts Weigh in on Innoviva Stock
Sep 30 2025
Benzinga
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts
Aug 11 2025
Benzinga
Innoviva (INVA) Q2 Sales Jump 64%
Aug 07 2025
NASDAQ.COM
Relative Strength Alert For Innoviva
Jul 28 2025
NASDAQ.COM
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Jul 14 2025
Benzinga
First Week of August 15th Options Trading For Innoviva (INVA)
Jun 23 2025
NASDAQ.COM
Show More News
